The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Dr Somnath Chatterjee
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250 and 1.4 pts less than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Dr. Somnath Chatterjee, Promoter, Chairman and Joint Managing Director of Suraksha Diagnostic Ltd, has acquired 7,590 equity shares of the company through an open market purchase on 13 June 2025. This filing is a disclosure under Regulation 29(2) of SEBI's SAST Regulations, 2011. His shareholding rose from 25,99,689 shares to 26,07,279 shares, taking his stake in the company to 5.01% of the total paid-up equity share capital (which stands at 5,20,80,758 shares of Rs 2 each). The purchase was a small, incremental acquisition by the promoter, signaling continued insider confidence in the company.
This is a minor insider purchase that nudges the promoter's stake marginally above 5%, but the size is too small to materially affect stock price. It may be viewed as a confidence signal by retail investors, though the promoter's overall holding remains well below 50%.